Helus Pharma (HELP) Market Performance
- Closing price: USD 11.06
- Trading change: −1.46 % during the 24‑hour period ending 04:03 PM Central Europe on Thursday 22 Oct 2026.
- Market capitalization: USD 770.9 million.
- Shares outstanding: 73.1 million.
- Volume traded (last 24 h): USD 10.1 million.
- Year‑to‑date change: −21.37 % since the end of last month.
- Simple moving average (200 days): USD 7.61.
- 52‑week high: USD 15.15 (18 Sep 2026).
- 52‑week low: USD 3.76 (9 Jun 2026).
Recent Corporate Filings
Helus Pharma Inc. has filed its latest regulatory disclosures, confirming continued compliance with reporting obligations. The filing indicates only a modest adjustment in the company’s trading position and no significant operational or strategic developments. The update confirms that Helus Pharma’s portfolio management remains aligned with market expectations and regulatory standards.
24‑Hour Performance of Related Stocks
| Ticker | Change | Current Price | Market Capitalisation | P/E Ratio |
|---|---|---|---|---|
| VMET.TO (Versamet Royalties) | +0.84 % | CAD 11.55 | CAD 1.3 bn | – |
| ASM.TO (Avino Silver & Gold Mines) | +0.27 % | CAD 6.90 | CAD 1.2 bn | 17.78 |
| ARG.TO (Amerigo) | –2.54 % | CAD 7.20 | CAD 1.3 bn | 16.16 |
| SGY.TO (Surge Energy) | +2.85 % | CAD 12.87 | CAD 1.3 bn | 28.69 |
| RGSI.TO (Rockpoint Gas Storage) | –1.20 % | CAD 23.46 | CAD 1.3 bn | 4.02 |
Avino Silver & Gold Mines reported a strong third‑quarter performance, with revenue growth driven by sustained demand. Operating income increased, reflecting effective cost management. The company maintained solid liquidity, supporting continued capital allocation to exploration and development. Management highlighted progress in key asset acquisitions and ongoing exploration activities, underscoring its focus on long‑term growth. Outlook remains supportive, with guidance indicating steady revenue momentum and margin stability.
Company Overview
Helus Pharma is a life sciences company headquartered in Toronto, Canada. The firm focuses on the development of psychedelic therapeutics, innovative delivery mechanisms, novel compounds, and clinical protocols. Helus Pharma serves a global customer base through its website at www.cybin.com and trades on the NYSE MKT stock exchange.
